24-AUG-2023 Tb-161 isotope will be linked to a proprietary monoclonal antibody (mAb) to form RAD 402, a radiotherapeutic being developed by our team to target KLK3 expression. KLK3 is highly expressed in prostate cancer cells but has limited expression in healthy tissue. We will initiate a Phase I dose escalating trial evaluating the safety and efficacy of RAD 402 in patients with advanced prostate cancer, during the second half of 2024.
12-JUL-2023 With the first dose Terbium-161 already delivered to Switzerland, we're pleased to announce that TerThera b.v. and Solumedics signed a distribution agreement for the region of Switzerland, Austria and Serbia.
15-JUN-2023 As Terbium-161 is considered as one of the most promising therapeutic radionuclides of the future, and as early research suggests having a higher anti-tumor capability for both primary and metastasized cancers, we will further build towards a sustainable and uninterrupted supply of Terbium-161 together meeting the increasing demand in cancer healthcare and ultimately helping cancer patients globally.
17-APR-2023 We are proud to announce our new partnership with Radiopharm Theranostics to help enable the development of a new generation of therapeutic radiopharmaceuticals with the supply of #Terbium161!
20-MAR-2023 We've reached the next milestone! With the shared effort of NRG and TerThera, a sustainable and uninterrupted supply of Terbium-161 is secured to meet the growing demand in cancer healthcare.
15-FEB-2023 First-in-human SPECT/CT Imaging using Tb-161 PSMA has been published confirming the ability to visualize previously identified lesions and providing for new insights in the application of Terbium-161! Reference Al-Ibraheem et al.
13-FEB-2023 The first case report on the application of Terbium-161 PSMA has been published with a promising observation on the therapeutic value of the treatment of disseminated metastatic disease using Terbium-161 for Radioligand Therapy (RLT). A single cycle, 6.5GBq Tb-161 PSMA RLT, showed an impressive decrease in PSA level (-53%) in one heavily pre-treated patient with highly advanced metastatic castration-resistant prostate cancer. PET/CT confirmed the significant decrease in tumor burden visualizing the partial remission. Reference Rosar et al
22-DEC-2022 This week we supplied our customers once again with high doses of Terbium-161 including a single order of 58GBq at pre-cal. Meaning, we can successfully close this year and look back on a beautiful operational start of TerThera BV earlier in August! We will continue to build the Terbium-161 platform in 2023 to meet the increasing demand to support preclinical and clinical initiatives.
Many thanks to the dedicated production team and to our greatest partners that allowed such a great start this year! To our community, we wish you all a great time with family and loved ones. Merry Christmas!
22-NOV-2022 We are proud to share that we once again were able to provide the highest activity Terbium161 (42GBq) to Saarland University Homburg. And from now on packaged in our new type A box model!
17-NOV-2022 Continuing our Terbium-161 production, we are ready to ship the next batch to our customers in Europe!
25-OCT-2022 Now with the dust settled we are looking back at a most successful European Association of Nuclear Medicine (EANM) Congress. As a start-up company we are genuinely grateful and proud to have shared our story and thoughts on Terbium161 with so many peers.
Thank you to all the attendees and we hope to meet once again during the next annual EANM congess in Vienna! In the meantime, look out for our next milestones where we will be ramping up our current Terbium161 production!
17-OCT-2022 The start of another day at the European Association of Nuclear Medicine (EANM). Please join as at booth #47 for a coffee and an introduction to #Terbium161!
10-OCT-2022 As one of the youngest companies in the nuclear industry, we will be present at the EANM this year. Join us for a coffee and the latest news on Terbium-161
with Stuart Koelewijn & Philippe van Overeem!
28-SEP-2022 A next step in the implementation of Terbium-161 into clinical routine: the successful delivery of the highest doses of Terbium-161 to Saarland University Homburg.
05-SEP-2022 Our second delivery of Terbium-161
has successfully arrived in Australia!
Due to the high level of requests for our product we are planning another high activity production in the last week of September 2022.
01-SEP-2022 The first delivery of high activity Terbium-161
was received in good order by the Saarland University Homburg!